A study on Lipase Reagent Market has been conducted to understand the landscape to 2022.
March 11-18, 2023
We conducted a survey of 545 market players of all sizes.
Number of valid answers:
Field survey 226, Internet survey 319
The survey was conducted among companies based on revenue.
Q: How big is the lipase reagent market?
The global lipase reagent market is estimated to garner up to USD 1,521 billion in revenue by the end of 2035, growing at a CAGR of up to 7% during the forecast period 2023-2035. Moreover, the market will generate revenue of approximately US$631 billion in 2022. Market growth can be attributed to an increase in patients suffering from various ailments such as vitamin deficiencies, dehydration,
malnutrition, high stomach acid, and persistent diarrhea.
The Lipase Test Reagent serves as an indicator to study the presence of pancreatic-related disorders and other stomach problems. The incidence of acute pancreatitis has increased from 28 per 100,000 population in 1999 to 36 per 100,000 population in 2010. About 14.8 million adults were diagnosed with ulcers in 2018, according to the Centers for Disease Control and Prevention. According to the World Gastroenterology Association, out of 100%, 49% of women and 36.6% of men reported the most common disorders such as constipation, diarrhea, IBS, proctomycosis and dyspepsia at 11.7% and 4.7% respectively. %, 4.1%, 5.9% and 7.2%.
Q: What are the key factors driving the growth of the lipase reagent market? The key factors driving the growth of the lipase reagent market are: More Diarrhea Cases in Children – According to the World Health Organization, 1.7 billion children suffer from diarrhea each year worldwide.
Growing Concerns About Diagnosis
Government initiatives in the healthcare sector
poor lifestyle and malnutrition
Lack of hygiene knowledge and unhygienic environment
Q: What are the challenges associated with the lipase reagent market? Challenges associated with the Lipase Reagent Market are:
Lack of adequate healthcare systems in low-income areas
Low awareness of diagnosis and stomach problems
High cost of treatment – When medical disorders indicated by higher lipase levels are treated, costs can be significant, especially if hospitalization, surgery, or long-term medications are required. In 2019, a quarter of U.S. adults, about 26%, reported having trouble paying their medical bills in 2018.
Q: How is the lipase reagent market segmented?
The lipase reagent market is segmented as follows:
o Turbidity method
o pancreatic disease
o Cystic fibrosis
Q: Which segment has the greatest growth based on application? Based on application, the global lipase reagent market is segmented and analyzed for demand and supply to hospitals, clinics, etc., of which the hospital segment is expected to hold the largest market size by the end of 2035. The market is estimated to grow due to the expansion of the healthcare sector and technological advances within the medical sector for diagnosis and treatment. Across OECD countries, health spending increased by 5% from 8.8% of GDP in 2019 to 9.7% of GDP in 2020, according to estimates by the Organization for Economic Co-operation and Development (OECD).
Q: Which segment has the greatest growth based on indication? Based on indication, the global lipase reagent market is also segmented and analyzed for supply and demand in pancreatic disorders, cancer, and cystic fibrosis. Among these segments, the pancreatic disease segment is projected to capture the highest market revenue by the end of 2035. This segment is growing on the fact that most cases of high lipase levels indicate a problem with the pancreas. Accurate and rapid diagnosis is essential for effective treatment and management of pancreatic disease, and measurement of lipase levels may be a critical step in this process. For example, in the United States, about 45-350 million out of every million people were found to suffer from acute pancreatitis.
Q: Who are the key players in the lipase reagents market? What are the recent developments in the market?
Major players in the lipase reagent market are DIALAB, DiaSys Diagnostic Systems GmbH, Sunson Industry Group Co., Ltd, Randox Laboratories Ltd., Abbott, Beckman Coulter, Inc., Biocompare, VitroScient, Merck Group, Sisco Research Laboratories Pvt. .is. Recent developments in the market include:
August 2021: AzuR
: Published positive results for MS1819 during a Phase 2 trial by evaluating MS1819 and porcine-derived pancreatic enzyme replacement therapy for treating severe exocrine pancreatic insufficiency in patients with cystic fibrosis.
April 2019: DiaSysDiagnostic Systems GmH
announced the development of Lipase DC FS, a state-of-the-art direct colorimetric assay with improved stability for pancreatic diagnostics. Q: Which regions are expected to offer lucrative growth opportunities for the lipase reagents market?
Lipase reagents in North America are projected to hold the largest market share by the end of 2035 on the back of growing people’s concerns about complications related to the gastrointestinal tract. Of the 440 million non-cancer diseases, over 22 million acute
gastrointestinal diseases have been reported, including 11 million cases of gastroenteritis and 6 million cases of dyspepsia. Besides, the North America region has excellent infrastructure and more hospitals driving the growth of the global lipase reagent market during the forecast period. The total number of all hospitals in the North America region is 6,000, with 920,000 staff beds in 2022. Moreover, the Asia-Pacific lipase reagent market is also growing rapidly due to the growing demand for lipase reagents in the pharmaceutical, food and beverage, and biotechnology sectors. The need for lipase reagents in the detection and treatment of
lifestyle-related diseases such as diabetes and obesity is increasing with their increasing prevalence. The need for lipase reagents for use in food evaluation and quality control is also growing as a result of the expanding regional food and beverage industry, especially in countries such as China and India.
About the company:
Research Nester (LAMORI PRIVATE LIMITED) goal is to help clients achieve their goals by providing efficient business solutions. Through our diverse network of research analysts and consultants, we help our clients understand all the key aspects of business valuation, including budgeting, to deliver strategic business solutions around the world. RNPL has earned trust and a customer base in over 30 countries, with an even greater focus on expansion into other economies. We are committed to providing our clients with the best possible service and helping them expand their scope of business. Details about this release: